EUVIMEDEUVIMED entdecken
Crossref

Could the concomitant use of beta blockers with bevacizumab improve survival in metastatic colon cancer?

Mehmet Zahid Kocak, Muhiddin Er, Muzaffer Ugrakli, Engin Hendem, Murat Araz, Melek Karakurt Eryilmaz, Mehmet Artac

European Journal of Clinical Pharmacology · 2023

DOI: 10.1007/s00228-023-03464-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Pharmacology, 2023. Verfasst von Mehmet Zahid Kocak und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey. mehmetzahidkocak@hotmail.com. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIM: Drug-drug interactions are sometimes neglected in oncology practice. Due to drug pharmacokinetic and pharmacodynamic interactions, clinically increased or decreased drug effects and increased or decreased adverse effects may occur. Considering that the concomitant use of these two drugs that affect vascular endothelial growth factor receptor (VEGFR) may cause pharmacological potentiation or additive interaction, we aimed to evaluate the survival outcomes of concomitant use of bevacizumab and beta blockers in patients with metastatic colorectal cancer (mCRC). METHODS: In total, 181 patients with mCRC administered with bevacizumab plus cytotoxic chemotherapy regimen in a first-line setting were divided into two groups: concomitant beta-blocker user and nonuser. RESULTS: The median overall survival (mOS) was 35.9 (95% CI: 27.9-43.9) months in the beta-blocker-using group and 29.6 (95% CI: 27.9-43.9) months in the beta-blocker-non-using group (p = 0.054). The median progression-free survival (mPFS) was 16.1 (95% CI: 12.4-19.9) months in the beta-blocker-using group and 12.8 (95% CI: 10.6-15.0) months in the beta-blocker-non-using group (p = 0.006). The multivariate analysis revealed that beta-blocker use was an independent predictor of mPFS (HR: 0.66, 95% CI: 0.46-0.93, p = 0.018) and mOS (HR: 0.57, 95% CI: 0.36-0.91, p = 0.02). CONCLUSION: This study demonstrated that concomitant usage of beta blockers improved both survival outcomes, irrespective of the kind of beta blocker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsColonic NeoplasmsRectal NeoplasmsHumansBevacizumabVascular Endothelial Growth Factor AAntineoplastic Combined Chemotherapy ProtocolsAdrenergic beta-AntagonistsFluorouracilDisease-Free Survival

Stichwörter der Autor:innen

Beta blockerBevacizumabColon cancerMetastasis

Substanzen

BevacizumabVascular Endothelial Growth Factor AAdrenergic beta-AntagonistsFluorouracil

Autor:innen und Institutionen

  • Department of Medical Oncology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey. mehmetzahidkocak@hotmail.com.
  • Department of Medical Oncology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey.

Zitieren

APA

Kocak, M. Z., Er, M., Ugrakli, M., Hendem, E., Araz, M., Eryilmaz, M. K., & Artac, M. (2023). Could the concomitant use of beta blockers with bevacizumab improve survival in metastatic colon cancer?. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-023-03464-w

Vancouver

Kocak MZ, Er M, Ugrakli M, Hendem E, Araz M, Eryilmaz MK, et al. Could the concomitant use of beta blockers with bevacizumab improve survival in metastatic colon cancer?. European Journal of Clinical Pharmacology. 2023. doi:10.1007/s00228-023-03464-w

BibTeX
@article{Kocak2023,
  author = {Kocak, Mehmet Zahid and Er, Muhiddin and Ugrakli, Muzaffer and Hendem, Engin and Araz, Murat and Eryilmaz, Melek Karakurt and Artac, Mehmet},
  title = {Could the concomitant use of beta blockers with bevacizumab improve survival in metastatic colon cancer?},
  journal = {European Journal of Clinical Pharmacology},
  year = {2023},
  doi = {10.1007/s00228-023-03464-w}
}
Kostenlos starten →